Science
Imagine a world where we could turn off the genes behind cancer development, progression, and treatment resistance.
What if we could also deliver the medicines directly to the tumor – with the hope of reducing the terrible side-effects associated with cancer treatment?
SirnaMed is making that world a reality
Our approach to cancer treatment begins with siRNA, and designing compounds that can silence genes with exquisite specificity. We then pair our siRNAs with chemotherapeutic agents, and co-encapsulate them in one of our two proprietary tumor-targeted polymeric nanoparticle platforms; Combo and siRNA-alone.
Our nanoparticles are our signature
With our targeted delivery platforms, we hope to achieve direct delivery of the siRNA with or without a chemotherapy drug to the tumors - and not anywhere else, maximizing efficacy and minimizing side-effects.
SirnaMed
